
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a clinical-stage biotechnology company with a product candidate, Neflamapimod, that has shown potential to improve synaptic dysfunction in age-related neurologic disorders. The company's recent Phase 2a trial in patients with dementia with Lewy bodies (DLB) showed promising results, with the drug slowing disease worsening in patients with low plasma pTau181 levels. With a pivotal trial in DLB planned and potential revenue from other indications, CervoMed has a strong outlook for further success. Additionally, the company's patent position has been strengthened, and mid-stage trial results in patients with non-fluent variant primary progressive aphasia (nfvPPA) are expected shortly. This positive news, along with the potential for a strategic partnership and further clinical successes, indicates a positive outlook for CervoMed's stock.
Bears say
CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The primary product candidate, Neflamapimod, has shown promising results in clinical trials for treating age-related neurologic disorders, particularly in DLB. However, the recent data analysis shows that the dose selection for the pivotal assessment may not be optimal, and there is a risk of future delay in initiating the Phase 3 trial. Additionally, there is a possibility of dilution risk in the medium term, which could impact the company's valuation and stock price.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares